Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISU104 in Advanced Solid Tumors and HNSCC
NCT03552406Phase 1Unknown
- Sponsor
- ISU Abxis Co., Ltd.
- Start
- Apr 2018
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of barecetamab in solid tumor and head and neck squamous cell carcinoma (HNSCC) (7 arms), sponsored by ISU Abxis Co., Ltd. Primary endpoint: Recommended Phase II Dose at 4 weeks. Status: unknown.
02
Drugs
barecetamab
03
Conditions
solid tumorhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03552406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03552406.